Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993717 · ClinicalTrials.gov registry record
Solid Organ Transplant SHINGRIX
A clinical trial, sponsored by Emory University.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03993717 is a clinical trial that was terminated before completion, run by Emory University. The registered enrollment target is 2 participants.
The verdict
NCT03993717 was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and aim to better understand if the vaccine and perhaps other adjuvanted vaccines are safe in these patients. 30 participants will be divided into 2 groups, one group will receive the 1st out of 2 doses of the vaccine 3-6 months after transplant per standard of care and the second group will receive the 1st out of 2 doses of the vaccine 12-36 months after the transplant per standard of care.The duration of the study is 180 days.
Interventions
- BIOLOGICAL SHINGRIX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2020-08-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993717
The ClinicalTrials.gov registry entry for NCT03993717 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SHINGRIX is the first listed.
NCT03993717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03993717 about?
NCT03993717 is a clinical study titled "Solid Organ Transplant SHINGRIX". This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and aim to better understand if the vaccine and perhaps other adjuvanted v...
What is the current status of trial NCT03993717?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-01-30. Estimated completion is 2020-08-08.
What interventions are being tested in trial NCT03993717?
The interventions under investigation include: SHINGRIX (BIOLOGICAL).
Who is sponsoring clinical trial NCT03993717?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.